Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: A population-based perspective

Cancer

Volumn 115, Issue 24, 2009, Pages 5680-5687

  Lughezzani, Giovanni ^a,b   Capitanio, Umberto ^a,b   Jeldres, Claudio ^a   Isbarn, Hendrik ^a,c   Shariat, Shahrokh F ^a   Arjane, Philippe ^d   Widmer, Hugues ^d   Perrotte, Paul ^d   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cytoreductive nephrectomy; Kidney; Lymph node status; Lymphadenectomy; Metastatic renal cell carcinoma; Prognostic schemes; Survival; TNM staging

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS;

EID: 73149112849     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24682     Document Type: Article

References (20)

1. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:992-993.
2. Elmore JM, Kadesky KT, Koeneman KS, Sagalowsky A. Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer. 2003;98:2329-2334.
3. Terrone C, Cracco C, Porpiglia F, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006;49:324-331.
4. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
5. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174:1759-1763; discussion 63.
6. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559-4566.
7. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25:1316-1322.
8. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/ 1975-2005/ Accessed on January 10, 2009.
9. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer. 2007;109:868-874.
10. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
11. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68-72.
12. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006;175(3 pt 1):864-869.
13. Karakiewicz PI, Lewinshtein DJ, Chun FK, et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol. 2006;50:521-528; discussion 29.
14. Capitanio U, Jeldres C, Patard JJ, et al. Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. BJU Int. 2009;103:33-37.
15. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169:2076-2083.
16. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003;97:2995-3002.
17. Karakiewicz PI, Trinh QD, de la Taille A, et al. ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. Eur J Cancer. 2007;43:1023-1029.
18. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2008;55:28-34.
19. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;(1):CD001425.
20. Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 2009;73:342-346.